Adipo Therapeutics, is an Indiana-based, small business developing a clinically translatable technology platform of polymer-based Notch-inhibiting nanoparticles, injected directly into adipose tissue, to induce beige adipocyte biogenesis as a safe, tolerable and effective treatment for type 2 diabetes (T2D) and obesity. The Adipo therapy is currently in preclinical development.
Adipo Therapeutics is developing a disruptive technology platform composed of polymer-based nanoparticulate drug delivery systems to induce adipocyte browning as a safe and effective therapeutic solution to treat obesity. This innovation combines the recent discovery of the role played by Notch signaling in adipocyte plasticity with advances in polymer-based drug delivery. This technology offers several unique value propositions including sustainable weight loss, improved glucose homeostasis and systemic metabolism, and minimized off-target side effects. Such an enabling technology platform can also be readily adapted to treat a broad spectrum of diseases such as fatty liver disease and atherosclerosis.